Mesa Laboratories (MLAB) AI Stock Analysis

• Market Cap: $402.02M
• Dividend Yield: 0.84%
• Average Volume (3M): 172.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: 8.33%
• EPS Growth: 99.75%
• Country: US
• Employees: 736
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 2.32
• Shares Outstanding: 5,501,454
• 10 Day Avg. Volume: 100,182
• 30 Day Avg. Volume: 172,556
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.71
• Enterprise Value/Revenue: 2.83
• Enterprise Value/Gross Profit: 4.70
• Enterprise Value/Ebitda: 15.38
• 1Y Price Target: $82.67
• Price Target Upside: 8.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 50 Neutral
• Price Target: $71.00 ▼(-7.12% Downside)

Mesa Laboratories' overall stock score is primarily influenced by its mixed financial performance, with strong revenue growth but profitability challenges. Technical analysis shows moderate bullish momentum, while valuation concerns due to a negative P/E ratio weigh heavily on the score. The lack of earnings call and corporate events data limits additional insights.

Mesa Laboratories Business Overview & Revenue Model

Company Description

Mesa Laboratories, Inc. (MLAB) is a publicly traded company specializing in the development and manufacturing of electronic monitoring and control instruments, primarily for the healthcare, pharmaceutical, and biotechnology sectors. The company operates through several segments, including its Biopharmaceutical Development Services, which provides tools and services for regulatory compliance and quality assurance, and its Medical Device segment, which focuses on temperature and pressure monitoring solutions. Mesa Laboratories is known for its core products such as data loggers, sterilization indicators, and various quality assurance instruments that help businesses maintain compliance with industry standards.

How the Company Makes Money

Mesa Laboratories generates revenue through the sale of its specialized monitoring and control instruments, as well as through its services related to biopharmaceutical development and regulatory compliance. Key revenue streams include the direct sale of products such as data loggers, sterilization indicators, and related software solutions. The company also earns income from service contracts and consulting related to compliance and quality assurance. Significant partnerships with healthcare facilities, pharmaceutical companies, and biotechnology firms enhance its market reach and contribute to its earnings, as these clients rely on Mesa's products to ensure regulatory compliance and maintain quality standards in their operations.

Mesa Laboratories Financial Statement Overview

Summary

Mesa Laboratories shows strong revenue growth and gross margins, but profitability is a concern with negative net margins and ROE. Improved leverage management is noted, but cash flow challenges persist with declining free cash flow growth.

Income Statement

Mesa Laboratories shows a mixed performance in its income statement. The TTM gross profit margin is strong at 62.1%, indicating efficient cost management. However, the net profit margin is negative, reflecting ongoing profitability challenges. Revenue growth is robust at 57% TTM, but the negative EBIT and EBITDA margins in previous years highlight operational inefficiencies.

Balance Sheet

The balance sheet presents a moderate financial position. The debt-to-equity ratio has improved to 0.67 TTM from higher levels, suggesting better leverage management. However, the negative return on equity indicates that the company is not generating positive returns for shareholders. The equity ratio remains stable, reflecting a balanced asset structure.

Cash Flow

Cash flow analysis reveals some strengths, with a positive operating cash flow to net income ratio of 0.26 TTM, indicating effective cash generation relative to earnings. However, the free cash flow growth is negative, which could impact future investments. The free cash flow to net income ratio is strong, suggesting good cash conversion.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	242.35M	240.98M	216.19M	219.08M	184.34M	133.94M
Gross Profit	146.12M	150.87M	133.25M	133.69M	109.09M	87.01M
EBITDA	44.66M	42.35M	-238.38M	36.45M	29.77M	12.36M
Net Income	-620.00K	-1.97M	-254.25M	930.00K	1.87M	3.27M
Balance Sheet
Total Assets	435.74M	433.35M	446.80M	661.83M	707.37M	600.15M
Cash, Cash Equivalents and Short-Term Investments	21.28M	27.32M	28.21M	32.91M	49.35M	263.87M
Total Debt	184.94M	181.47M	231.30M	170.27M	221.13M	146.70M
Total Liabilities	263.25M	273.52M	301.40M	268.35M	313.57M	193.92M
Stockholders Equity	172.50M	159.83M	145.39M	393.48M	393.80M	406.23M
Cash Flow
Free Cash Flow	33.65M	42.31M	41.57M	23.44M	34.79M	35.08M
Operating Cash Flow	38.27M	46.81M	44.13M	27.98M	39.22M	37.07M
Investing Cash Flow	-4.62M	-4.50M	-81.31M	-9.49M	-305.23M	-1.99M
Financing Cash Flow	-43.83M	-44.51M	32.84M	-33.33M	52.58M	146.23M

Mesa Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 76.44
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLAB, the sentiment is Positive. The current price of 76.44 is above the 20-day moving average (MA) of 69.79, above the 50-day MA of 67.86, and below the 200-day MA of 102.60, indicating a neutral trend. The MACD of 1.54 indicates Negative momentum. The RSI at 60.84 is Neutral, neither overbought nor oversold. The STOCH value of 84.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MLAB.

Mesa Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYTS	77 Outperform	$700.62M	27.98	11.21%	0.87%	22.09%	-5.26%
DAKT	68 Neutral	$969.63M	4,540.91	4.36%	―	-7.67%	7.66%
RELL	66 Neutral	$161.45M	506.94	0.11%	2.19%	6.17%	―
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
VPG	61 Neutral	$489.47M	112.76	-0.39%	―	-11.47%	-106.18%
LPTH	56 Neutral	$389.97M	―	-37.15%	―	17.26%	-70.07%
MLAB	50 Neutral	$402.02M	―	-0.38%	0.84%	8.33%	99.75%

Mesa Laboratories Corporate Events

Mesa Laboratories Holds Annual Shareholder Meeting

On August 22, 2025, Mesa Laboratories held its annual meeting of shareholders where 5,203,377 shares were represented. During the meeting, the election of directors was confirmed, with John J. Sullivan, Gary M. Owens, Jenny S. Alltoft, Shannon M. Hall, Shiraz S. Ladiwala, R. Tony Tripeny, and Mark C. Capone elected to the board for a one-year term. The board also appointed members to its committees. Additionally, the shareholders ratified the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. The compensation of the company’s named executive officers was approved on a non-binding basis, and an amendment to the 2021 Equity Incentive Plan was also approved.

Mesa Laboratories Draws $97M for Convertible Notes Settlement

On August 12, 2025, Mesa Laboratories, Inc. drew $97 million from its existing Credit Facility to fund the settlement of its outstanding convertible notes that matured on August 15, 2025. This strategic financial move, part of a plan announced in April 2024, aims to optimize Mesa’s capital structure and reduce potential shareholder dilution. The company expects to benefit from future interest rate reductions and plans to make significant principal payments in fiscal year 2026, demonstrating its commitment to prudent financial management and shareholder value.